Mike V. Gormally, MD PhD

Medical Oncologist @sloan_kettering
Scientist and Drug Discoverer in @KlebanoffLab
Vertical adventurer 🏔

[Mike V. Gormally, MD PhD @GormallyMDPHD]

🔬 New from our group in @JAMAOncology: Germline HLA genotyping must become standard as #HLA restricted therapies expand. Crucial for #Immunotherapy and #PrecisionOncology @MonicaChenMD @AdamJSchoenfeld @KlebanoffLab 🧵1/8 https://t.co/cqWa4Gd7f3

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Tomorrow at #ESMO25: MSK’s Dr. Michael Gormally (@GormallyMDPHD) will discuss pan-cancer mapping of HLA class I loss of #heterozygosity in a 50,000 patient cohort which reveals prognostic clinical implications for HLA-restricted therapies. @myESMO

Learn more: https://t.co/OW3960zCeg

[Mike V. Gormally, MD PhD @GormallyMDPHD]

📢New MS out now, where we pair real-world clinical data from patients at @MSKCancerCenter with HLA zygosity derived from #IMPACT to detect HLA loss and its effect on survival, an increasingly important biomarker in the age of immunotherapies. https://t.co/xuni9Gausx

[Klebanoff_Lab @KlebanoffLab]

🚨Today, in @NatureCancer, we show that CAR-T cells and CAR-NK cells contain the seeds of their own self-destruction. Disruption of a FAS-L/FAS circuit enhances CAR potency against liquid and solid cancers. https://t.co/afS9vRG4Ok @MSKCancerCenter @parkerici @MSK_DeptOfMed

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Happening now: MSK research fellow @GormallyMDPHD presents results from a real-world analysis evaluating HLA LOH frequencies and survival outcomes in #cancer at #AACR25.

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK physician-scientist @KlebanoffLab talked about all things #neoantigens for the Novel Classes of Human Cancer Rejection Antigens session this morning at #AACR25.

[Mike V. Gormally, MD PhD @GormallyMDPHD]

🏥 On the horizon in the clinic: Many new HLA-restricted trials in 2025, majority public #neoantigen-specific #TCR-T, including #MSKCC's first #KRAS #TCR-T produced in-house @AdamJSchoenfeld #ACT 8/8

[Mike V. Gormally, MD PhD @GormallyMDPHD]

🔬 New from our group in @JAMAOncology: Germline HLA genotyping must become standard as #HLA restricted therapies expand. Crucial for #Immunotherapy and #PrecisionOncology @MonicaChenMD @AdamJSchoenfeld @KlebanoffLab 🧵1/8 https://t.co/cqWa4Gd7f3

[Mike V. Gormally, MD PhD @GormallyMDPHD]

🧑‍🔬On the horizon at the bench: Watch for future work led by @chaiband & @KlebanoffLab diving into HLA loss of heterozygosity amongst this same 60K-patient cohort. 7/8

[Mike V. Gormally, MD PhD @GormallyMDPHD]

@JetBlue heading to airport with BPs/assigned seats. Get email saying I CANCELLED?? Call in, agents say I "called in on a recorded line and cancelled." Refuse to help/believe that of course I didn't! DM w/full details...I need you to reply and say how this ID breach happened

[Mike V. Gormally, MD PhD @GormallyMDPHD]

So proud! Immense gratitude to Chris and the rest of the @KlebanoffLab for such fantastic mentorship, to @ConquerCancerFd for 💸💸💸 to support us, and all cancer patients @StoCANcer and beyond, whose contributions are central to how we discover novel T cell therapies⬇️⬇️⬇️

[Klebanoff_Lab @KlebanoffLab]

Congrats to @GormallyMDPHD on his very well deserved ASCO Young Investigator Award to support his research developing best in class #TCRs targeting recurrent #TP53 hotspot mutations! @MSK_DeptOfMed @MSKCancerCenter @ConquerCancerFd @ASCO #Tcellpower

[Adam J. Schoenfeld @AdamJSchoenfeld]

Excited to see our phase 2 multicenter study of Tumor-Infiltrating Lymphocyte in Advanced #LungCancer Resistant to Immunotherapy in @CD_AACR. #TIL #Celltherapy https://t.co/y3VD1urjUa

[Klebanoff_Lab @KlebanoffLab]

What is the "Holy Grail" of tumor antigens❓ Found out in our lab's recent interview with The Scientist (@TheScientistLLC )👇. @MSKCancerCenter @parkerici #Tcellpower

https://t.co/eDFNiI0HrC

[Klebanoff_Lab @KlebanoffLab]

🚨Pre-print alert: Here, we show that CAR-T *and* CAR-NK persistence is negatively self-regulated through activation dependent FAS ligand expression. Further highlights FAS as an actionable molecule to enhance cell therapies. @parkerici @MSKCancerCenter
https://t.co/fPDHx5x5ev